amiodarone has been researched along with Syncope in 44 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Syncope: A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Induction of rapid ventricular tachycardia or fibrillation during therapy with amiodarone is associated with an increased risk of sudden death." | 9.06 | Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. ( Buxton, AE; Flores, BT; Josephson, ME; Marchlinski, FE; Miller, JM; Vassallo, JA, 1986) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 8.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 7.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "Five cases of amiodarone-induced polymorphous ventricular tachycardia (torsade de pointes) are presented." | 7.66 | Amiodarone-induced polymorphous ventricular tachycardia. ( Agmon, J; Arditti, A; Kracoff, O; Lewin, RF; Sclarovsky, S; Strasberg, B, 1983) |
| "A patient with the familial syndrome of Q-T prolongation, ventricular arrhythmias, and syncope was effectively treated with amiodarone." | 7.66 | Effective management of the long q-t syndrome with amiodarone. ( Bashour, T; Cheng, TO; Jokhadar, M, 1981) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 5.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "The effects of two regimens for the initiation of amiodarone therapy were compared in 92 patients with inducible sustained ventricular tachycardia (VT) at baseline electrophysiologic testing." | 5.07 | A comparison of standard and high-dose regimens for the initiation of amiodarone therapy. ( Kadish, A; Morady, F; Summitt, J, 1992) |
| "Induction of rapid ventricular tachycardia or fibrillation during therapy with amiodarone is associated with an increased risk of sudden death." | 5.06 | Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. ( Buxton, AE; Flores, BT; Josephson, ME; Marchlinski, FE; Miller, JM; Vassallo, JA, 1986) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 4.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 3.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "A 55-year-old patient with inferior wall infarction was treated effectively for ventricular tachycardia with high-dose oral amiodarone loading regimen (5 g within 16 hours)." | 3.68 | Antiadrenergic cardiovascular adverse effects of high-dose amiodarone loading regimen. ( Frey, B; Schmidinger, H; Steurer, G, 1992) |
| "ES was, therefore, of diagnostic value in more than half of the patients with syncope of unknown cause and long-term treatment based on ES was successful in the prevention of S (remission rate of 93% in patients treated with amiodarone or pacemaker)." | 3.67 | [Usefulness of the electrophysiologic study in the prognostic evaluation of patients with syncope of uncertain origin]. ( Bernardi, G; Feruglio, GA; Fontanelli, A; Gianfagna, P; Proclemer, A, 1987) |
| "Five cases of amiodarone-induced polymorphous ventricular tachycardia (torsade de pointes) are presented." | 3.66 | Amiodarone-induced polymorphous ventricular tachycardia. ( Agmon, J; Arditti, A; Kracoff, O; Lewin, RF; Sclarovsky, S; Strasberg, B, 1983) |
| "A patient with the familial syndrome of Q-T prolongation, ventricular arrhythmias, and syncope was effectively treated with amiodarone." | 3.66 | Effective management of the long q-t syndrome with amiodarone. ( Bashour, T; Cheng, TO; Jokhadar, M, 1981) |
| "A long Q-T interval syndrome is described, followed by "torsade de pointe" and by irriducible ventricular fibrillation that is ascribed to a badly conducted therapy with amiodarone, in a patient affected by mitral valve disease, microcitaemia and hemolitic intercurrent moderate jaundice." | 3.66 | ["T'orsade de pointe" and amiodarone (author's transl)]. ( Guerricchio, G; Scandiffio, T; Veglia, L, 1978) |
| "Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD)." | 2.73 | Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. ( Anderson, J; Bardy, GH; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Olshansky, B; Packer, D; Poole, JE, 2008) |
| "An elderly woman had ventricular tachycardia, and her defibrillator failed to discharge." | 1.51 | Wide-QRS Tachycardia in an 89-Year-Old Woman With an ICD. ( Glancy, DL; Kawji, MM, 2019) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal inherited arrhythmia syndrome induced by adrenergic stress." | 1.48 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. ( Duan, H; Hua, Y; Li, Y; Lu, Y; Qiao, L; Wang, C; Yan, S; Zhou, K, 2018) |
| "Ventricular tachycardia is a life threatening cardiac arrhythmia." | 1.46 | Fatal monomorphic ventricular tachycardia in a semi-urban setting in Cameroon: a case report. ( Dikoume, L; Luchuo, EB; Nkoke, C, 2017) |
| "Recent infection was present in 40." | 1.39 | Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. ( Ajrouche, R; Al-Hajje, A; Awada, S; El-Helou, N; Rachidi, S; Salameh, P; Zein, S, 2013) |
| "Syncope may be a manifestation of pulmonary embolism." | 1.35 | Entrapment of a floating thrombus in the right atrium by persistent Chiari's network: a barrier to massive pulmonary embolism. ( Colizzi, C; Lombardo, A; Pennestrì, F; Rizzello, V, 2009) |
| "Sustained monomorphic ventricular tachycardia was defined as a tachycardia with uninterrupted duration or rapid recurrence despite automatic internal cardiac defibrillator therapy for at least 5 minutes before amiodarone treatment, monomorphic morphology, rate greater than 120 beats/min, QRS duration greater than 120 ms, and subsequently determined to be ventricular tachycardia by ECG criteria (eg, atrioventricular dissociation), implanted device interrogation, or formal electrophysiology study." | 1.33 | Amiodarone is poorly effective for the acute termination of ventricular tachycardia. ( deSouza, IS; Marill, KA; Nishijima, DK; Ruskin, JN; Setnik, GS; Stair, TO, 2006) |
| "All arrhythmias were treated successfully by pacemaker/ICD implantation, radiofrequency catheter ablation and/or medications." | 1.33 | The utility of implantable loop recorders for diagnosing unexplained syncope in 100 consecutive patients: five-year, single-center experience. ( Cohen, T; Inamdar, V; Juang, G; Mehta, S, 2006) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 1.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "Arrhythmogenic right ventricular dysplasia is an inherited, progressive condition." | 1.31 | Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition. ( Fisher, NG; Gilbert, TJ, 2000) |
| "Although syncope is a frequent clinical entity, the evaluation and treatment of patients with syncope without a clear etiology still remains undefined." | 1.30 | [Patients with structural heart disease, syncope of unknown etiology and inducible ventricular arrhythmias treated with implantable defibrillators]. ( Aguinaga, L; Anguera, I; Brugada, J; Matas, M; Mont, L; Valentino, M, 1998) |
| "Amiodarone was clinically useful in 32 (68%) patients." | 1.28 | Use of amiodarone for short-term and adjuvant therapy in young patients. ( Benson, DW; Deal, BJ; Pongiglione, G; Strasburger, JF, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (25.00) | 18.7374 |
| 1990's | 10 (22.73) | 18.2507 |
| 2000's | 13 (29.55) | 29.6817 |
| 2010's | 8 (18.18) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Kawji, MM | 1 |
| Glancy, DL | 1 |
| Arias, MA | 1 |
| Pachón, M | 1 |
| Loughlin, G | 1 |
| Mazzanti, A | 1 |
| Guz, D | 1 |
| Trancuccio, A | 1 |
| Pagan, E | 1 |
| Kukavica, D | 1 |
| Chargeishvili, T | 1 |
| Olivetti, N | 1 |
| Biernacka, EK | 1 |
| Sacilotto, L | 1 |
| Sarquella-Brugada, G | 1 |
| Campuzano, O | 1 |
| Nof, E | 1 |
| Anastasakis, A | 1 |
| Sansone, VA | 1 |
| Jimenez-Jaimez, J | 1 |
| Cruz, F | 1 |
| Sánchez-Quiñones, J | 1 |
| Hernandez-Afonso, J | 1 |
| Fuentes, ME | 1 |
| Średniawa, B | 1 |
| Garoufi, A | 1 |
| Andršová, I | 1 |
| Izquierdo, M | 1 |
| Marinov, R | 1 |
| Danon, A | 1 |
| Expósito-García, V | 1 |
| Garcia-Fernandez, A | 1 |
| Muñoz-Esparza, C | 1 |
| Ortíz, M | 1 |
| Zienciuk-Krajka, A | 1 |
| Tavazzani, E | 1 |
| Monteforte, N | 1 |
| Bloise, R | 1 |
| Marino, M | 1 |
| Memmi, M | 1 |
| Napolitano, C | 1 |
| Zorio, E | 1 |
| Monserrat, L | 1 |
| Bagnardi, V | 1 |
| Priori, SG | 1 |
| Nkoke, C | 1 |
| Luchuo, EB | 1 |
| Dikoume, L | 1 |
| Duan, H | 1 |
| Lu, Y | 1 |
| Yan, S | 1 |
| Qiao, L | 1 |
| Hua, Y | 1 |
| Li, Y | 1 |
| Zhou, K | 1 |
| Wang, C | 1 |
| El-Helou, N | 1 |
| Al-Hajje, A | 1 |
| Ajrouche, R | 1 |
| Awada, S | 1 |
| Rachidi, S | 1 |
| Zein, S | 1 |
| Salameh, P | 1 |
| Stiefelhagen, P | 1 |
| Beyer, A | 1 |
| Ganti, B | 1 |
| Majkrzak, A | 1 |
| Theyyunni, N | 1 |
| Gopinathannair, R | 1 |
| Mazur, A | 1 |
| Olshansky, B | 2 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Ross, JJ | 1 |
| Britton, KA | 1 |
| Desai, AS | 1 |
| Stevenson, WG | 2 |
| D'Ascenzi, F | 1 |
| Iadanza, A | 1 |
| Zacà, V | 1 |
| Pierli, C | 1 |
| Mondillo, S | 1 |
| Willan, AR | 1 |
| Chen, EB | 1 |
| Cook, RJ | 1 |
| Lin, DY | 1 |
| Aouate, P | 1 |
| Elbaz, N | 1 |
| Klug, D | 1 |
| Lacotte, J | 1 |
| Raguin, D | 1 |
| Frank, R | 1 |
| Lelouche, D | 1 |
| Dubois-Randé, JL | 1 |
| Tonet, J | 1 |
| Fontaine, G | 1 |
| Kozák, M | 1 |
| Izákovicová Hollá, L | 1 |
| Krivan, L | 1 |
| Vasků, A | 1 |
| Sepsi, M | 1 |
| Semrád, B | 1 |
| Vácha, J | 1 |
| Marill, KA | 1 |
| deSouza, IS | 1 |
| Nishijima, DK | 1 |
| Stair, TO | 1 |
| Setnik, GS | 1 |
| Ruskin, JN | 1 |
| Inamdar, V | 1 |
| Mehta, S | 1 |
| Juang, G | 1 |
| Cohen, T | 1 |
| Lim, HE | 1 |
| Pak, HN | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kim, YH | 1 |
| Davis, JE | 1 |
| Curtis, LA | 1 |
| Rashid, H | 1 |
| Rizzello, V | 1 |
| Lombardo, A | 1 |
| Colizzi, C | 1 |
| Pennestrì, F | 1 |
| Poole, JE | 1 |
| Johnson, G | 1 |
| Anderson, J | 1 |
| Hellkamp, AS | 1 |
| Packer, D | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 1 |
| Morady, F | 2 |
| Shen, E | 1 |
| Schwartz, A | 1 |
| Hess, D | 1 |
| Bhandari, A | 1 |
| Sung, RJ | 1 |
| Scheinman, MM | 1 |
| Sclarovsky, S | 1 |
| Lewin, RF | 1 |
| Kracoff, O | 1 |
| Strasberg, B | 1 |
| Arditti, A | 1 |
| Agmon, J | 1 |
| Bashour, T | 1 |
| Jokhadar, M | 1 |
| Cheng, TO | 1 |
| Makkar, RR | 1 |
| Fromm, BS | 1 |
| Steinman, RT | 1 |
| Meissner, MD | 1 |
| Lehmann, MH | 1 |
| Stevenson, LW | 1 |
| Middlekauff, HR | 1 |
| Saxon, LA | 1 |
| Rapezzi, C | 1 |
| Spirito, P | 1 |
| Winters, SL | 1 |
| Sachs, RG | 1 |
| Curwin, JH | 1 |
| Aguinaga, L | 1 |
| Mont, L | 1 |
| Anguera, I | 1 |
| Valentino, M | 1 |
| Matas, M | 1 |
| Brugada, J | 1 |
| Fisher, NG | 1 |
| Gilbert, TJ | 1 |
| Alboni, P | 1 |
| Veglia, L | 1 |
| Scandiffio, T | 1 |
| Guerricchio, G | 1 |
| Brochier, M | 1 |
| Fauchier, JP | 1 |
| Charbonnier, B | 1 |
| Latour, F | 1 |
| Perrotin, D | 1 |
| Steurer, G | 1 |
| Schmidinger, H | 1 |
| Frey, B | 1 |
| Summitt, J | 1 |
| Kadish, A | 1 |
| Pongiglione, G | 1 |
| Strasburger, JF | 1 |
| Deal, BJ | 1 |
| Benson, DW | 1 |
| Wyndham, CR | 1 |
| Proclemer, A | 1 |
| Gianfagna, P | 1 |
| Fontanelli, A | 1 |
| Bernardi, G | 1 |
| Feruglio, GA | 1 |
| Kracoff, OH | 1 |
| Ovsyshcher, I | 1 |
| Gueron, M | 1 |
| Marchlinski, FE | 1 |
| Buxton, AE | 1 |
| Miller, JM | 1 |
| Vassallo, JA | 1 |
| Flores, BT | 1 |
| Josephson, ME | 1 |
| Dorian, P | 1 |
| Waldecker, B | 1 |
| Brugada, P | 1 |
| Zehender, M | 1 |
| Stevenson, W | 1 |
| Den Dulk, K | 1 |
| Wellens, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reveal® In-Office Implants Study[NCT01168427] | 66 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| [NCT00000609] | Phase 3 | 0 participants | Interventional | 1997-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This objective estimates the proportion of patients having procedure-related complication requiring resolution by surgical intervention at 90 days post-implant procedure using Kaplan-Meier method. (NCT01168427)
Timeframe: From Implant to 90 days post-implant procedure
| Intervention | participants (Number) |
|---|---|
| Implant Cohort | 2 |
Report number of participants having procedure-related adverse events that meet the primary endpoint (requiring surgical intervention), and number of participants having other procedure-related adverse events (not requiring surgical intervention). (NCT01168427)
Timeframe: From Implant to 90 days post-implant procedure
| Intervention | participants (Number) | |
|---|---|---|
| AEs that meet the primary endpoint | Other procedure-related AEs | |
| Implant Cohort | 2 | 4 |
5 reviews available for amiodarone and Syncope
| Article | Year |
|---|---|
Syncope in congestive heart failure.
Topics: Aged; Aged, 80 and over; Amiodarone; Combined Modality Therapy; Defibrillators, Implantable; Electro | 2008 |
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid | 1993 |
Sudden death prevention in patients with advanced ventricular dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, Su | 1993 |
Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Humans; Infusions, | 1997 |
Role of invasive electrophysiologic testing in the management of life-threatening ventricular arrhythmias.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Electrophysiology; Heart | 1988 |
3 trials available for amiodarone and Syncope
| Article | Year |
|---|---|
Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Death, Sudden, Cardiac; Defibrillators, | 2008 |
A comparison of standard and high-dose regimens for the initiation of amiodarone therapy.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Drug Administration Schedule; Female; Heart Conduction | 1992 |
Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Death, Sudden; Drug Evaluation; Drug Therapy, Combination; Female; Follow-U | 1986 |
36 other studies available for amiodarone and Syncope
| Article | Year |
|---|---|
Wide-QRS Tachycardia in an 89-Year-Old Woman With an ICD.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electrocardiogra | 2019 |
New Onset Recurrent Syncope Triggered by Fever.
Topics: Amiodarone; Coronary Angiography; Drug Therapy, Combination; Electric Countershock; Electrocardiogra | 2020 |
Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Andersen Syndrome; Anti-Arrhythmia Agent | 2020 |
Fatal monomorphic ventricular tachycardia in a semi-urban setting in Cameroon: a case report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cameroon; Electrocardiography; Fatal Outcome; Heart Rate; | 2017 |
A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Death, Sudden, Cardiac; Delayed Diagnosis; Electrocardiog | 2018 |
Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Inflammatory Agen | 2013 |
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap | 2015 |
A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiotonic Agents; Electric Cou | 2017 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
Interactive medical case. The beat goes on.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Bundle-Branch Block; Cardiomyopathy, Dilated; Def | 2010 |
Subocclusion of the sinus node artery during coronary angioplasty: arrhythmological considerations.
Topics: Acute Coronary Syndrome; Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Atrial | 2010 |
Incremental net benefit in randomized clinical trials with quality-adjusted survival.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Health Care Costs; Heart Arrest; Humans; | 2003 |
[Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial | 2002 |
Endothelin-1 gene polymorphism in patients with malignant arrhythmias.
Topics: Aged; Amino Acid Sequence; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, | 2004 |
Amiodarone is poorly effective for the acute termination of ventricular tachycardia.
Topics: Aged; Aged, 80 and over; Amiodarone; Combined Modality Therapy; Dose-Response Relationship, Drug; El | 2006 |
The utility of implantable loop recorders for diagnosing unexplained syncope in 100 consecutive patients: five-year, single-center experience.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia | 2006 |
Torsade de pointes induced by short-term oral amiodarone therapy.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillat | 2006 |
Idiopathic cardiac electrical storm.
Topics: Adrenergic beta-Antagonists; Amiodarone; Drug Therapy, Combination; Electrocardiography; Humans; Mal | 2009 |
Entrapment of a floating thrombus in the right atrium by persistent Chiari's network: a barrier to massive pulmonary embolism.
Topics: Adult; Amiodarone; Echocardiography, Transesophageal; Enzyme Inhibitors; Heart Atria; Heart Valves; | 2009 |
Long-term follow-up of patients with recurrent unexplained syncope evaluated by electrophysiologic testing.
Topics: Amiodarone; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Mitral Valve Prolapse; Pacem | 1983 |
Amiodarone-induced polymorphous ventricular tachycardia.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cardiac Pacing, Artificial; Electrocardiography | 1983 |
Effective management of the long q-t syndrome with amiodarone.
Topics: Adolescent; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; Heart Ventricles; Hu | 1981 |
[Cardiac decompensation and syncope].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Heart Failure; Humans | 1994 |
[Therapy of arrhythmias in hypertrophic cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomy | 1995 |
Assessment of the cardiac patient for fitness to drive: 1996 update.
Topics: Amiodarone; Arrhythmias, Cardiac; Automobile Driving; Defibrillators, Implantable; Electrocardiograp | 1996 |
[Patients with structural heart disease, syncope of unknown etiology and inducible ventricular arrhythmias treated with implantable defibrillators].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia | 1998 |
Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2000 |
[The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillat | 2002 |
["T'orsade de pointe" and amiodarone (author's transl)].
Topics: Amiodarone; Benzofurans; Female; Humans; Middle Aged; Mitral Valve Insufficiency; Syncope; Tachycard | 1978 |
[Beneficial effects of injectable amiodarone on syncope in Prinzmetal's angina].
Topics: Amiodarone; Angina Pectoris; Angina Pectoris, Variant; Benzofurans; Drug Evaluation; Humans; Infusio | 1976 |
Antiadrenergic cardiovascular adverse effects of high-dose amiodarone loading regimen.
Topics: Administration, Oral; Amiodarone; Cardiac Output, Low; Catecholamines; Humans; Male; Middle Aged; My | 1992 |
Use of amiodarone for short-term and adjuvant therapy in young patients.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Arrhythmias, Cardi | 1991 |
[Usefulness of the electrophysiologic study in the prognostic evaluation of patients with syncope of uncertain origin].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Female; Follo | 1987 |
Malignant course of a benign anomaly: myocardial bridging.
Topics: Adult; Amiodarone; Cardiomyopathies; Coronary Angiography; Diltiazem; Electrocardiography; Electroph | 1987 |
Syncope, tachycardia, and exertional dyspnea.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiac Catheterization; Coronary Disease; Dyspnea; Elect | 1985 |
Importance of modes of electrical termination of ventricular tachycardia for the selection of implantable antitachycardia devices.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Disease; Humans; Male; Middle | 1986 |